Charlie CY Yang, an analyst from Bank of America Securities, maintained the Buy rating on Merck & Company (MRK – Research Report). The associated price target is $140.00. Charlie CY Yang has ...

(RTTNews) - Drug major Merck & Co., Inc. (MRK) announced Wednesday that the U.S. Food and Drug Administration has approved its anti-PD-1 therapy KEYTRUDA (pembrolizumab), in combination with ...

This marks Keytruda's first approval for the given indication. Merck (MRK) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

NJBIZ, New Jersey’s leading business journal, provides 24/7 business news coverage and events honoring top business professionals.

with the German firm’s Merck Serono division licensing various technologies used to engineer T-cells to target cancers, including its RheoSwitch platform for controlling gene expression and ...

After hours: September 20 at 7:52 PM EDT Loading Chart for MRK ...

Analysts see big upside for these undervalued health care stocks.

During an R&D update yesterday Merck said it is hoping to claim eight new cardiovascular therapy approvals between now and 2030, for diseases like atherosclerosis, heart failure, pulmonary ...

The previous Paralympic logo incorporated the Tae-Geuk, which is a traditional Korean decorative motif. According to oriental philosophy, Tae-Geuk refers to the ultimate reality from which all things ...